Merck to Acquire Acceleron Pharma Inc – “Merck aspire to be the premier research-intensive biopharmaceutical company in the world”

in Industry Report, Healthcare & Life Sciences on November 17, 2021

The deal would be the largest biopharma acquisition this year, and a sign that Merck is willing to spend more than usual to diversify its business beyond the cancer drug Keytruda. The company also completed a strategic divesture this year to improve its focus on key growth areas. Merck completed Organon & Co. Spinoff in Jun-21, and believes the transaction will deliver significant benefits for both companies.

The deal also adds FDA-approved blood-related disorder drug Reblozyl, which Acceleron markets with partner Bristol Myers Squibb (BMY.N), to Merck’s portfolio.

• Executive Summary

• Deal Overview

• Company Overview – Acceleron Pharma Inc

• Company Overview – Merck & Co., Inc.

No of Pages : 65

Release Information

  • Released
    :

    November 17, 2021

  • Last Updated
    :

    December 2, 2021